ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma.

. The crude incidence of malignant melanoma in the European Union is 10/100 000 per year. The incidence increases with latitude, i.e. with increasing prevalence of less pigmented skin types, from 3–5/100 000 per year in Mediterranean countries to 12–17 in Nordic countries. The mortality is 2.4/100 000 per year with a lesser variation with geography. Increased ultraviolet-B ray exposure seems responsible for an ongoing increase in incidence over recent decades.

[1]  M. Gore,et al.  Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. R. Farmer,et al.  NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.

[3]  Raymond L. Barnhill,et al.  Long-Term Results of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margins for 740 Patients With 1–4 mm Melanomas , 2001, Annals of Surgical Oncology.

[4]  J. Thomas,et al.  Excision margins in high-risk malignant melanoma. , 2004, The New England journal of medicine.

[5]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[7]  M. Urist,et al.  Melanoma recurrence surveillance. Patient or physician based? , 1995, Annals of surgery.

[8]  P. Schlag,et al.  Isolated Limb Perfusion with Tumor Necrosis Factor-Alpha and Melphalan , 2007 .

[9]  B. Redman,et al.  Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon , 2004, Psycho-oncology.

[10]  E. Bissonette,et al.  Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Neuberg,et al.  Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673) , 2004, Cancer.